Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Clinical trial NCT06376721 · RECRUITING

Trial details

NCT number: NCT06376721
Sponsor: Beijing Tongren Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type T-lymphoblastic Lymphoma

Start date: 2024-04-14
Primary completion: 2026-10-31
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.